Skip to main content
AAN.com

Abstract

Ataxia telangiectasia (AT) is a rare autosomal-recessive disorder caused by mutations in the AT-mutated (ATM) gene (chromosome 11q 22-23) with absent or aberrant ATM protein kinase.1 It is usually characterized by childhood-onset cerebellar ataxia, oculocutaneous telangiectasia, oculomotor apraxia, immunodeficiency, increased malignancy risk, and early mortality (classical AT).1 Recently it has become apparent that a spectrum of milder adult-onset phenotypes exist (variant AT), associated with residual expression of functional ATM protein.2,3 These patients demonstrate a predominance of extrapyramidal features, later age at ataxia onset, slower progression, and an extended lifespan. We report the case of a woman first diagnosed with AT at the unusually late age of 60.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair 2004;3:1187–1196.
2.
Verhagen MM, Abdo WF, Willemsen MA, et al. Clinical spectrum of ataxia-telangiectasia in adulthood. Neurology 2009;73:430–437.
3.
Verhagen MM, Last JI, Hogervorst FB, et al. Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. Hum Mutat 2012;33:561–571.
4.
Dork T, Bendix-Waltes R, Wegner RD, Stumm M. Slow progression of ataxia-telangiectasia with double missense and in frame splice mutations. Am J Med Genet A 2004;126A:272–277.
5.
Micol R, Ben Slama L, Suarez F, et al. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Allergy Clin Immunol 2011;128:382–389.
6.
Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005;97:813–822.

Information & Authors

Information

Published In

Neurology® Clinical Practice
Volume 4Number 4August 2014
Pages: 365-367

Publication History

Published online: February 24, 2014
Published in print: August 2014

Permissions

Request permissions for this article.

Disclosures

The authors report no disclosures. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.

Study Funding

No targeted funding reported.

Authors

Affiliations & Disclosures

Laurence Newrick, BMedSci
University of Sheffield Medical School (LN); University of Birmingham Medical School (NS); and Department of Neurology (MH), Royal Hallamshire Hospital, Sheffield, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Noor Sharrack
University of Sheffield Medical School (LN); University of Birmingham Medical School (NS); and Department of Neurology (MH), Royal Hallamshire Hospital, Sheffield, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Marios Hadjivassiliou, MD
University of Sheffield Medical School (LN); University of Birmingham Medical School (NS); and Department of Neurology (MH), Royal Hallamshire Hospital, Sheffield, UK.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence to: [email protected]
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Atypical Ataxia Presentation in Variant Ataxia Telangiectasia: Iranian Case-Series and Review of the Literature, Frontiers in Immunology, 12, (2022).https://doi.org/10.3389/fimmu.2021.779502
    Crossref
  2. Functional analysis of ATM variants in a high risk cohort provides insight into missing heritability, Cancer Genetics, 264-265, (40-49), (2022).https://doi.org/10.1016/j.cancergen.2022.03.003
    Crossref
  3. Genetic predisposition to lymphomas: Overview of rare syndromes and inherited familial variants, Mutation Research/Reviews in Mutation Research, 788, (108386), (2021).https://doi.org/10.1016/j.mrrev.2021.108386
    Crossref
  4. TREC/KREC levels in children with ataxia-telangiectasia, Immunologic Research, 69, 5, (436-444), (2021).https://doi.org/10.1007/s12026-021-09216-1
    Crossref
  5. Trajectories of motor abnormalities in milder phenotypes of ataxia telangiectasia, Neurology, 92, 1, (e19-e29), (2018)./doi/10.1212/WNL.0000000000006700
    Abstract
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share